SOURCE: Stem Cell Therapy International, Inc.

July 28, 2006 14:51 ET

Stem Cell Therapy International Names Aidman, Piser & Co., Tampa, FL, as Its Auditors

TAMPA, FL -- (MARKET WIRE) -- July 28, 2006 --Stem Cell Therapy International, Inc., (PINKSHEETS: SCII) a company in the field of regenerative medicine providing research, development and the treatment of patients with stem cell transplantation therapy, today announced that is has engaged Aidman, Piser & Company, Certified Public Accountants, Tampa, FL, as its new auditors.

Aidman, Piser is a member of DFK International, a major international network of independent accounting firms and business advisers. The network has 293 offices across the world with each member firm reflecting its local business environment.

Calvin Cao, chairman and chief executive officer of Stem Cell Therapy International, said, "Aidman, Piser's international footprint is the prime factor that encouraged us to change our auditors. Though we were satisfied with the services we received, given the international nature of SCTI's operations, it has become increasingly necessary to work with auditors with cross border experience."

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to fund stem cell research. Since then four other states, New Jersey, Connecticut, Illinois and Wisconsin, have allocated funds for stem cell research. For additional information, please visit our website @ www.scticorp.com.

About Stem Cell Therapy International (SCTI)

Stem Cell Therapy International, Inc. is engaged in the field of research and development of regenerative medicine. SCTI's affiliated clinic manufactures stem cell biological solutions that are currently being used in the treatment of patients suffering from degenerative disorders of the human body such as MS, stroke, diabetes, Alzheimer's, Parkinson's Disease, ALS, leukemia, muscular dystrophy, arthritis, spinal cord injuries, brain injury, heart disease, liver and retinal disease as well as certain types of cancer and can be used to alleviate the side effects of chemotherapy. The Company has filed a provisional patent describing the successful process in the treatment of severe burns with Cryopreserved human stem cells. This technique will be used in other type of cosmetic applications such as the prevention of scar tissue after surgery and for skin rejuvenation therapy. SCTI has established agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI intends to provide these biological solutions containing stem cell products in the United States as well to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials. Its products, which are available now, include various stem cell biological solutions containing human stem cells, low-molecular proteins, nutrients and human growth factor hormones.

Forward-Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.

Contact Information

  • For more information, please contact:

    Stem Cell Therapy International
    Calvin C. Cao
    Chairman and CEO
    Stem Cell Therapy International
    E: calvin@scticorp.com

    Stem Cell Therapy International
    Peter K. Sidorenko
    Chief Operating Officer
    Stem Cell Therapy International
    E: peter@scticorp.com

    Investor Relations
    Arun Chakraborty
    Investor Relations
    Stern & Co.
    T: 212-888-0044
    E: achakrab@sternco.com

    Media Relations
    Stan Froelich
    VP, Media Relations
    Stern & Co.
    T: 212-888-0044
    E: sfroelich@sternco.com